These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial. Draelos ZD, Gold MH, Weiss RA, Baumann L, Grekin SK, Robinson DM, Kempers SE, Alvandi N, Weng E, Berk DR, Ahluwalia G. J Am Acad Dermatol; 2018 Jun; 78(6):1156-1163. PubMed ID: 29409914 [Abstract] [Full Text] [Related]
10. A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment. Berth-Jones J, Grotzinger K, Rainville C, Pham B, Huang J, Daly S, Herdman M, Firth P, Hotchkiss K. Br J Dermatol; 2006 Oct; 155(4):707-13. PubMed ID: 16965419 [Abstract] [Full Text] [Related]
18. Objectively quantifying facial erythema in rosacea aided by the ImageJ analysis of VISIA red images. Tao M, Li M, Zhang Y, Liu Y, Jiang P, Liu Y, Xu Y. Skin Res Technol; 2023 Jan; 29(1):e13241. PubMed ID: 36426837 [Abstract] [Full Text] [Related]
19. Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1·0% for persistent erythema of rosacea in a phase IV study. Eichenfield LF, Del Rosso JQ, Tan JKL, Hebert AA, Webster GF, Harper J, Baldwin HE, Kircik LH, Stein-Gold L, Kaoukhov A, Alvandi N. Br J Dermatol; 2019 May; 180(5):1050-1057. PubMed ID: 30500065 [Abstract] [Full Text] [Related]